Diagnostic Value of PET Tracers in Differentiating Glioma Tumor Recurrence from Treatment-Related Changes: A...

It is often difficult to identify treatment-related changes (TRC) from tumor progression (TP) in patients with glioma, and the current application of PET scanning is expected to improve the diagnosis.

We used a systematic review and meta-analysis to reveal diagnostically more promising tracers by comparing the diagnostic accuracy of different PET tracers in identifying TRC and TP in patients with glioma.

We searched PubMed, Web of Science, and EMBASE databases, and we selected studies that used PET scans to identify TP and TRC in patients with glioma.

Twenty-eight studies were identified based on the set criteria. The studies involved a total of 10 different tracers and 1405 patients. TP occurred in 67.4% (947) of patients, while TRC occurred in 32.6% (458) of patients.

The sensitivity, specificity, diagnostic odds ratio, positive likelihood ratio, and negative likelihood ratio of various PET tracers were calculated and summarized. Moreover, the diagnostic value of various tracers was compared.

This systematic review included 28 studies comparing 10 different PET tracers, including ¹⁸F-fluoro-deoxy-glucose FDG (¹⁸F-FDG), ¹¹C methionine (¹¹C -MET), ¹⁸F-fuoroethyl-L-tyrosine (¹⁸F-FET), 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine (¹⁸F-FDOPA), ¹⁸F-fluorothymidine (¹⁸F-FLT), ¹⁸F-PSMA-1007, ⁶⁸Ga-PSMA-11, ¹⁸F-choline (¹⁸F-CHO), ¹⁸F-fluciclovine, and [¹¹]C-Alpha-Methyl-Tryptophan(¹¹C-AMT). The results revealed that ¹¹C-MET exhibited the highest diagnostic value, with an overall sensitivity and specificity of 0.89 [0.85, 0.93] and 0.91 [0.84, 0.99], respectively. Although the number of ¹⁸F-FDOPA studies is limited, it exhibited high diagnostic value, with an overall sensitivity and specificity of 1.00 [0.91, 1.00] and 0.92 [0.75, 0.99], respectively.

Most studies consisted of small sample sizes; however, the included studies differed to some extent regarding the reference standard for the final diagnosis and the standard of care. Additionally, most selected studies were retrospective.

Amino acid-based tracers exhibited the highest diagnostic value in identifying TRC and TP in gliomas, with ¹¹C-MET and ¹⁸F-FDOPA having the most notable advantages. Research on other new tracers is limited, therefore, further studies are needed to prove their diagnostic value.